Harith Akram1, Sarah Miller2, Susie Lagrata2, Jonathan Hyam2, Marjan Jahanshahi2, Marwan Hariz2, Manjit Matharu2, Ludvic Zrinzo2. 1. From the Unit of Functional Neurosurgery (H.A., J.H., M.J., M.H., L.Z.), Sobell Department of Motor Neuroscience and Movement Disorders, UCL Institute of Neurology, University College London; Victor Horsley Department of Neurosurgery (H.A., J.H., L.Z.), National Hospital for Neurology and Neurosurgery, London; Headache Group (S.M., S.L., M.M.), Institute of Neurology and National Hospital for Neurology and Neurosurgery, London, UK; and Department of Neurosurgery (M.H.), University Hospital, Umeå, Sweden. harith.akram.12@ucl.ac.uk. 2. From the Unit of Functional Neurosurgery (H.A., J.H., M.J., M.H., L.Z.), Sobell Department of Motor Neuroscience and Movement Disorders, UCL Institute of Neurology, University College London; Victor Horsley Department of Neurosurgery (H.A., J.H., L.Z.), National Hospital for Neurology and Neurosurgery, London; Headache Group (S.M., S.L., M.M.), Institute of Neurology and National Hospital for Neurology and Neurosurgery, London, UK; and Department of Neurosurgery (M.H.), University Hospital, Umeå, Sweden.
Abstract
OBJECTIVE: To present outcomes in a cohort of medically intractable chronic cluster headache (CCH) patients treated with ventral tegmental area (VTA) deep brain stimulation (DBS). METHODS: In an uncontrolled open-label prospective study, 21 patients (17 male; mean age 52 years) with medically refractory CCH were selected for ipsilateral VTA-DBS by a specialist multidisciplinary team including a headache neurologist and functional neurosurgeon. Patients had also failed or were denied access to occipital nerve stimulation within the UK National Health Service. The primary endpoint was improvement in the headache frequency. Secondary outcomes included other headache scores (severity, duration, headache load), medication use, disability and affective scores, quality of life (QoL) measures, and adverse events. RESULTS: Median follow-up was 18 months (range 4-60 months). At the final follow-up point, there was 60% improvement in headache frequency (p = 0.007) and 30% improvement in headache severity (p = 0.001). The headache load (a composite score encompassing frequency, severity, and duration of attacks) improved by 68% (p = 0.002). Total monthly triptan intake of the group dropped by 57% posttreatment. Significant improvement was observed in a number of QoL, disability, and mood scales. Side effects included diplopia, which resolved in 2 patients following stimulation adjustment, and persisted in 1 patient with a history of ipsilateral trochlear nerve palsy. There were no other serious adverse events. CONCLUSIONS: This study supports that VTA-DBS may be a safe and effective therapy for refractory CCH patients who failed conventional treatments. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that VTA-DBS decreases headache frequency, severity, and headache load in patients with medically intractable chronic cluster headaches.
OBJECTIVE: To present outcomes in a cohort of medically intractable chronic cluster headache (CCH) patients treated with ventral tegmental area (VTA) deep brain stimulation (DBS). METHODS: In an uncontrolled open-label prospective study, 21 patients (17 male; mean age 52 years) with medically refractory CCH were selected for ipsilateral VTA-DBS by a specialist multidisciplinary team including a headache neurologist and functional neurosurgeon. Patients had also failed or were denied access to occipital nerve stimulation within the UK National Health Service. The primary endpoint was improvement in the headache frequency. Secondary outcomes included other headache scores (severity, duration, headache load), medication use, disability and affective scores, quality of life (QoL) measures, and adverse events. RESULTS: Median follow-up was 18 months (range 4-60 months). At the final follow-up point, there was 60% improvement in headache frequency (p = 0.007) and 30% improvement in headache severity (p = 0.001). The headache load (a composite score encompassing frequency, severity, and duration of attacks) improved by 68% (p = 0.002). Total monthly triptan intake of the group dropped by 57% posttreatment. Significant improvement was observed in a number of QoL, disability, and mood scales. Side effects included diplopia, which resolved in 2 patients following stimulation adjustment, and persisted in 1 patient with a history of ipsilateral trochlear nerve palsy. There were no other serious adverse events. CONCLUSIONS: This study supports that VTA-DBS may be a safe and effective therapy for refractory CCH patients who failed conventional treatments. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that VTA-DBS decreases headache frequency, severity, and headache load in patients with medically intractable chronic cluster headaches.
Authors: T Foltynie; L Zrinzo; I Martinez-Torres; E Tripoliti; E Petersen; E Holl; I Aviles-Olmos; M Jahanshahi; M Hariz; P Limousin Journal: J Neurol Neurosurg Psychiatry Date: 2010-06-22 Impact factor: 10.154
Authors: Denys Fontaine; Michel Lanteri-Minet; Lemlih Ouchchane; Yves Lazorthes; Patrick Mertens; Serge Blond; G Geraud; Nelly Fabre; Malou Navez; Christian Lucas; Francois Dubois; Jean Christophe Sol; Philippe Paquis; Jean Jacques Lemaire Journal: Brain Date: 2010-03-17 Impact factor: 13.501
Authors: Thomas E Schlaepfer; Bettina H Bewernick; Sarah Kayser; Burkhard Mädler; Volker A Coenen Journal: Biol Psychiatry Date: 2013-04-03 Impact factor: 13.382
Authors: Gavin J B Elias; Aaron Loh; Dave Gwun; Aditya Pancholi; Alexandre Boutet; Clemens Neudorfer; Jürgen Germann; Andrew Namasivayam; Robert Gramer; Michelle Paff; Andres M Lozano Journal: Brain Date: 2021-04-12 Impact factor: 13.501
Authors: Megan L Settell; Paola Testini; Shinho Cho; Jannifer H Lee; Charles D Blaha; Hang J Jo; Kendall H Lee; Hoon-Ki Min Journal: Front Neurosci Date: 2017-03-03 Impact factor: 4.677